Should individualised benefit-harm assessment be a core part of real-world research?
Benefit-risk (of harm) assessment is the cornerstone of decision making in medical care [1]. Aggregated clinical trial data plays a critical role in both bringing treatments to market (by informing licensing and reimbursement) and in informing treatment decisions made...
Vitaccess strengthens leadership team with appointment of Matt Reaney as Chief Scientific Officer
London, UK – 13 April 2026, Vitaccess, a leader in generating science-driven real-world evidence, today announced the appointment of Matt Reaney as Chief Scientific Officer (CSO), expanding the company’s executive team. Matt brings over two decades of experience...
Vitaccess announces first-of-its-kind CIDP Registry and first patient enrolled in landmark patient-centered evidence platform
Boston, MA, USA and London, UK – 8 April 2026, Vitaccess, a leader in generating science-driven real-world evidence, announces the launch of the Vitaccess Real CIDP Registry, a first-of-its-kind patient-centered registry in chronic inflammatory demyelinating...
Putting Patients First: From Language to Real-World Evidence in Myasthenia Gravis Research
You’ve been part of Vitaccess’ journey from localisation into leading commercial relationships. What have been the biggest turning points for you, and for the company, during that time? I’ve been on the Vitaccess rollercoaster since the start-up days to now being a...
